Multiple Myeloma (MM) Profile in Brazil: A Retrospective Observational Analysis
NCT ID: NCT03506386
Last Updated: 2021-02-08
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
943 participants
OBSERVATIONAL
2018-08-09
2020-01-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of People With Multiple Myeloma (MM) in Portugal (CharisMMa-Portugal)
NCT04135963
Cohort Construction and Prognostic Model Construction for Multiple Myeloma
NCT06366802
An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants
NCT02761187
Impact of Paramedical Consultations in Oncological Supportive Care in Outpatients With Multiple Myeloma
NCT05355987
A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment
NCT04035226
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will enroll approximately 1000 participants.
This multi-center trial will be conducted in five geographic regions of Brazil. For each participant, data collection will comprise the longest possible period of time since the diagnosis of MM (within the eligibility window of time, between January 1, 2008 and December 31, 2016) and the cut-off date for data collection (December 31, 2016), unless a participant has died or been lost to follow-up before that. The study is planned to last for approximately 24 months since its initiation (initiation defined as the initiation visit for the first site).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Multiple Myeloma Participants
Participants with multiple myeloma (MM) were observed retrospectively since the diagnosis up to death or lost to follow-up within the eligibility window of time (between January 1, 2008 and December 31, 2016), in this study.
No Intervention
As it was an observational study, no intervention was administered.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No Intervention
As it was an observational study, no intervention was administered.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Documented diagnosis of MM by the responsible physician between January 1, 2008, and December 31, 2016.
3. Absence of any plasma-cell disorder other than MM.
4. Absence of any immunoglobulin-related disorder other than MM.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Takeda
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor Clinical Science
Role: STUDY_DIRECTOR
Takeda
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centro de Hematologia e Oncologia (CEHON)
Salvador, Estado de Bahia, Brazil
Hospital Sao Rafael
Salvador, Estado de Bahia, Brazil
Hospital das Clinicas da UFG
Goiânia, Goiás, Brazil
Hospital das Clinicas da UFMG
Belo Horizonte, Minas Gerais, Brazil
Fundacao IMEPEN
Juiz de Fora, Minas Gerais, Brazil
Clinica de Tratamento e Pesquisa em Hematologia LTDA.
Cuiabá, Mount, Brazil
Hospital das Clinicas da UFPR
Curitiba, Paraná, Brazil
CIONC - Centro Integrado de Oncologia de Curitiba
Curitiba, Paraná, Brazil
Universidade Federal do Rio de Janeiro
Rio de Janeiro, Rio de Janeiro, Brazil
Hospital Sao Vicente de Paulo
Passo Fundo, Rio Grande do Sul, Brazil
Hospital de Clinicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Centro de Pesquisas Oncologicas (CEPON)
Florianópolis, Santa Catarina, Brazil
Hospital Amaral Carvalho
Jaú, São Paulo, Brazil
Hospital do Servidor Publico de SP
São Paulo, São Paulo, Brazil
Clinica Sao Germano
São Paulo, São Paulo, Brazil
Hospital das Clinicas da FMUSP
São Paulo, São Paulo, Brazil
Casa de Saude Santa Marcelina
São Paulo, São Paulo, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NDMM-5004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.